PMID- 28074660
OWN - NLM
STAT- MEDLINE
DCOM- 20171023
LR  - 20180213
IS  - 1744-8336 (Electronic)
IS  - 1478-7210 (Linking)
VI  - 15
IP  - 4
DP  - 2017 Apr
TI  - Optimizing the management of children with latent tuberculosis infection.
PG  - 341-349
LID - 10.1080/14787210.2017.1279541 [doi]
AB  - The management of latent tuberculosis (LTBI) in children represents an important 
      issue for paediatricians because of the disease burden, the lack of a gold 
      standard for the diagnosis and the high annual risk of progression to active 
      disease. Areas covered: A review of English language articles on LTBI in 
      children, published between the 1st of January 2010 and the 1st of July 2016, was 
      conducted using multiple keywords and standardized terminology in PubMed 
      database. This review provides an updated overview of the available tests for 
      LTBI diagnosis in children, management strategies and treatment options. Expert 
      commentary: Two tests are available for LTBI diagnosis: tuberculin skin test and 
      interferon-gamma release assays, both with a suboptimal specificity and 
      sensitivity, and both with the lack of capability in distinguishing between 
      infection and disease. Several new markers have been identified but further 
      studies are needed. Among all treatment regimes, because of the high safety and 
      efficacy profile showed and to avoid the poor completion rate, the treatment with 
      a three-month course of isoniazid and rifampicin is currently recommended. New 
      vaccines are needed because of the spread of the disease despite BCG vaccination 
      in high risk countries. Currently, 15 new vaccines are in the pipeline.
FAU - Venturini, E
AU  - Venturini E
AD  - a Department of Health Sciences , University of Florence, Anna Meyer Children's 
      University Hospital , Florence , Italy.
FAU - Tersigni, C
AU  - Tersigni C
AD  - a Department of Health Sciences , University of Florence, Anna Meyer Children's 
      University Hospital , Florence , Italy.
FAU - Chiappini, E
AU  - Chiappini E
AD  - a Department of Health Sciences , University of Florence, Anna Meyer Children's 
      University Hospital , Florence , Italy.
FAU - de Martino, M
AU  - de Martino M
AD  - a Department of Health Sciences , University of Florence, Anna Meyer Children's 
      University Hospital , Florence , Italy.
FAU - Galli, L
AU  - Galli L
AD  - a Department of Health Sciences , University of Florence, Anna Meyer Children's 
      University Hospital , Florence , Italy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20170116
PL  - England
TA  - Expert Rev Anti Infect Ther
JT  - Expert review of anti-infective therapy
JID - 101181284
RN  - 0 (Antitubercular Agents)
RN  - 0 (Biomarkers)
RN  - 0 (CXCL10 protein, human)
RN  - 0 (Chemokine CXCL10)
RN  - 0 (Tuberculosis Vaccines)
RN  - 82115-62-6 (Interferon-gamma)
RN  - V83O1VOZ8L (Isoniazid)
RN  - VJT6J7R4TR (Rifampin)
SB  - IM
MH  - Antitubercular Agents/*therapeutic use
MH  - Biomarkers/blood
MH  - Chemokine CXCL10/*blood
MH  - Child
MH  - Disease Management
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Enzyme-Linked Immunospot Assay
MH  - Humans
MH  - Interferon-gamma/*blood
MH  - Isoniazid/therapeutic use
MH  - Latent Tuberculosis/*diagnosis/drug therapy/immunology/prevention & control
MH  - Mycobacterium tuberculosis/*drug effects/growth & development/immunology
MH  - Rifampin/therapeutic use
MH  - Tuberculin Test
MH  - Tuberculosis Vaccines/administration & dosage/biosynthesis
MH  - Tuberculosis, Pulmonary/*diagnosis/drug therapy/immunology/prevention & control
OTO - NOTNLM
OT  - Latent tuberculosis
OT  - children
OT  - diagnosis
OT  - management
OT  - treatment
EDAT- 2017/01/12 06:00
MHDA- 2017/10/24 06:00
CRDT- 2017/01/12 06:00
PHST- 2017/01/12 06:00 [pubmed]
PHST- 2017/10/24 06:00 [medline]
PHST- 2017/01/12 06:00 [entrez]
AID - 10.1080/14787210.2017.1279541 [doi]
PST - ppublish
SO  - Expert Rev Anti Infect Ther. 2017 Apr;15(4):341-349. doi: 
      10.1080/14787210.2017.1279541. Epub 2017 Jan 16.